CytoMed Therapeutics Ltd (nasdaq:GDTC) Share Price

Company Profile

Business description
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
Contact
1 Commonwealth Lane
No. 08-22 One Commonwealth
Singapore149544
SGP
T: +65 62507738
https://w2.cytomed.sg
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
42

Recommended

Corning’s optical fiber business is thriving, and the Meta deal derisks its supply buildout, but success isn’t guaranteed.

Ananya Chag | 27 April 2026

From AI integration to capital expenditure increases, here’s what we expect in Alphabet’s earnings report.

Malik Ahmed Khan, CFA | 24 April 2026

Santos reports a solid quarter on the back of higher commodity prices - yet the shares look undervalued.

Mark Taylor | 24 April 2026

Index	Last price	Change	% Change
All Ordinaries	8,935.00	14.40	-0.16%
CAC 40	8,104.09	37.83	-0.46%
DAX 40	24,018.26	65.27	-0.27%
Dow JONES (US)	49,149.94	17.85	-0.04%
FTSE 100	10,332.79	11.70	0.11%
HKSE	25,679.78	245.87	-0.95%
NASDAQ	24,635.23	251.87	-1.01%
Nikkei 225	59,917.46	619.90	-1.02%
NZX 50 Index	12,764.40	110.54	-0.86%
S&P 500	7,134.32	39.59	-0.55%
S&P/ASX 200	8,710.70	10.50	-0.12%
SSE Composite Index	4,078.64	7.71	-0.19%